Leonardo & Co. Advises Impact Lab

Leonardo & Co., in association with Houlihan Lokey, is pleased to announce that Impact Lab S.r.l., a portfolio company of Planven, has acquired TOMA Advanced Biomedical Assays S.p.A. (TOMA). In the context of the acquisition, Bootes S.r.l. and SAIT S.r.l. have entered the capital structure of Impact Lab. The Transaction closed on April 18, 2019.

Impact Lab, founded in 2015, is the holding company that controls 100% of Laboratorio di Analisi Mediche Martini S.r.l., an innovative diagnostic laboratory offering high-value-added products and services in molecular genetics utilized for analyses in oncology and reproductive technologies.

Impact Lab, renowned for its technology and R&D know-how, is an innovator of the Italian market experiencing rapid sustained growth. Notwithstanding its short history, Impact Lab offers its services across all of the Italian territories and is present abroad both directly to patients and through distributors.

TOMA is the first diagnostic laboratory to provide prenatal tests for genetic diseases and is currently among the most important laboratories in Europe with a strong scientific and clinical reputation in prenatal and postnatal genetic tests.

The combination of Impact Lab and TOMA will create the largest diagnostic laboratory in Italy for cytogenetics and molecular genetics.

Leonardo & Co., in association with Houlihan Lokey, served as sole financial advisor to Impact Lab in the context of the transaction, with activities ranging from the negotiation and structuring of the acquisition of TOMA to the capital-raising activities, including the search for new shareholders.